Nirsevimab: A Breakthrough in RSV Protection for Infants
A new antibody-based drug, nirsevimab, has shown to be 93% effective in preventing hospitalization and 89% effective in reducing doctor visits for RSV in infants, according to a study published in JAMA Pediatrics. Approved in 2023, nirsevimab provides lab-made antibodies to block RSV, offering a significant public health benefit if widely used. Despite its effectiveness, uptake has been low due to supply issues and timing of availability. The drug is recommended for infants under 8 months old, especially if their mothers haven't received the maternal RSV vaccine.